Consensus Statement of the Malignant Hyperthermia Association of the United States on Unresolved Clinical Questions Concerning the Management of Patients With Malignant Hyperthermia

At a recent consensus conference, the Malignant Hyperthermia Association of the United States addressed 6 important and unresolved clinical questions concerning the optimal management of patients with malignant hyperthermia (MH) susceptibility or acute MH. They include: (1) How much dantrolene should be available in facilities where volatile agents are not available or administered, and succinylcholine is only stocked on site for emergency purposes? (2) What defines masseter muscle rigidity? What is its relationship to MH, and how should it be managed when it occurs? (3) What is the relationship between MH susceptibility and heat- or exercise-related rhabdomyolysis? (4) What evidence-based interventions should be recommended to alleviate hyperthermia associated with MH? (5) After treatment of acute MH, how much dantrolene should be administered and for how long? What criteria should be used to determine stopping treatment with dantrolene? (6) Can patients with a suspected personal or family history of MH be safely anesthetized before diagnostic testing? This report describes the consensus process and the outcomes for each of the foregoing unanswered clinical questions.

• Publication year

  2019

• Venue

  Anesthesia and Analgesia

• Publication date

  2019-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1213/ANE.0000000000004039PMID 30768455
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Malignant Hyperthermia Susceptibility and Related Diseases.

  2018cited by this paper
• Heating and Cooling Rates With an Esophageal Heat Exchange System

  2017cited by this paper
• Is It Exertional Heatstroke or Something More? A Case Report.

  2016cited by this paper
• Identification of variants of the ryanodine receptor type 1 in patients with exertional heat stroke and positive response to the malignant hyperthermia in vitro contracture test.

  2016cited by this paper
• Prevalence of Malignant Hyperthermia Diagnosis in New York State Ambulatory Surgery Center Discharge Records 2002 to 2011

  2016cited by this paper
• 217th ENMC International Workshop: RYR1-related myopathies, Naarden, The Netherlands, 29-31 January 2016.

  2016cited by this paper
• Is There a Link between Exertional Heat Stroke and Susceptibility to Malignant Hyperthermia?

  2015cited by this paper
• Malignant Hyperthermia in Canada: Characteristics of Index Anesthetics in 129 Malignant Hyperthermia Susceptible Probands

  2014cited by this paper
• Malignant Hyperthermia Deaths Related to Inadequate Temperature Monitoring, 2007–2012: A Report from The North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States

  2014cited by this paper
• Malignant Hyperthermia in Children: An Analysis of the North American Malignant Hyperthermia Registry

  2014cited by this paper
• Functional and genetic characterization of clinical malignant hyperthermia crises: a multi-centre study

  2014cited by this paper
• Fever‐induced recurrent rhabdomyolysis due to a novel mutation in the ryanodine receptor type 1 gene

  2014cited by this paper
• Malignant hyperthermia in the ambulatory surgery center: how should we prepare?

  2014cited by this paper
• Acute kidney injury due to rhabdomyolysis and renal replacement therapy: a critical review

  2014cited by this paper
• Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis.

  2013cited by this paper
• Special article: Creation of a guide for the transfer of care of the malignant hyperthermia patient from ambulatory surgery centers to receiving hospital facilities.

  2012cited by this paper
• Activated Charcoal Effectively Removes Inhaled Anesthetics from Modern Anesthesia Machines

  2011cited by this paper
• Identical de novo Mutation in the Type 1 Ryanodine Receptor Gene Associated with Fatal, Stress-induced Malignant Hyperthermia in Two Unrelated Families

  2011cited by this paper
• Clinical Presentation, Treatment, and Complications of Malignant Hyperthermia in North America from 1987 to 2006

  2010cited by this paper
• Exertional rhabdomyolysis and malignant hyperthermia in a patient with ryanodine receptor type 1 gene, L-type calcium channel alpha-1 subunit gene, and calsequestrin-1 gene polymorphisms.

  2010cited by this paper
• The Myotonias and Susceptibility to Malignant Hyperthermia

  2009cited by this paper
• The ryanodine receptor type 1 gene variants in African American men with exertional rhabdomyolysis and malignant hyperthermia susceptibility

  2009cited by this paper
• RyR1 S-nitrosylation underlies environmental heat stroke and sudden death in Y522S RyR1 knockin mice.

  2008cited by this paper
• Exertional Heat Illness, Exertional Rhabdomyolysis, and Malignant Hyperthermia: Is There a Link?

  2008cited by this paper
• Analysis of the Clinical Variables Associated with Recrudescence after Malignant Hyperthermia Reactions

  2007cited by this paper
• Orphanet Journal of Rare Diseases BioMed Central Review Malignant hyperthermia

  2007cited by this paper
• Is there a link between malignant hyperthermia and exertional heat illness?

  2007cited by this paper
• Effects of a Circulating-water Garment and Forced-air Warming on Body Heat Content and Core Temperature

  2004cited by this paper
• Anaesthetic complications associated with myotonia congenita: case study and comparison with other myotonic disorders

  2003cited by this paper
• Malignant hyperthermia associated with exercise-induced rhabdomyolysis or congenital abnormalities and a novel RYR1 mutation in New Zealand and Australian pedigrees.

  2002cited by this paper
• Malignant hyperthermia and apparent heat stroke.

  2001cited by this paper
• A Noninvasive Investigation of Muscle Energetics Supports Similarities Between Exertional Heat Stroke and Malignant Hyperthermia

  2001cited by this paper
• Evidence for Susceptibility to Malignant Hyperthermia in Patients with Exercise-induced Rhabdomyolysis

  2001cited by this paper
• Core cooling by central venous infusion of ice-cold (4 degrees C and 20 degrees C) fluid: isolation of core and peripheral thermal compartments.

  2000cited by this paper
• Core Cooling by Central Venous Infusion of Ice-cold (4°C and 20°C) Fluid Isolation of Core and Peripheral Thermal Compartments

  2000cited by this paper
• Rhabdomyolysis following Severe Physical Exercise in a Patient with Predisposition to Malignant Hyperthermia

  1998cited by this paper
• Sudden unexplained death in a patient with a family history of malignant hyperthermia.

  1997cited by this paper
• Efficacy of Intraoperative Cooling Methods

  1997cited by this paper
• Creatine Kinase Alterations After Acute Malignant Hyperthermia Episodes and Common Surgical Procedures

  1995cited by this paper
• A Clinical Grading Scale to Predict Malignant Hyperthermia Susceptibility

  1994cited by this paper
• Masseter Muscle Rigidity and Malignant Hyperthermia Susceptibility in Pediatric Patients An Update on Management and Diagnosis

  1994cited by this paper
• Pathological findings in 165 patients explored for malignant hyperthermia susceptibility.

  1993cited by this paper
• Evidence for related myopathies in exertional heat stroke and malignant hyperthermia.

  1991cited by this paper
• Masseter Muscle Spasm in Children: Implications of Continuing the Triggering Anesthetic

  1991cited by this paper
• masseter Muscle Spasm in Children : implications of Continuing the Triggering Anesthetic

  1991cited by this paper
• Malignant hyperthermia susceptibility in adult patients with masseter muscle rigidity

  1990cited by this paper
• Myotonic and neuromuscular blocking effects of increased doses of suxamethonium in infants and children.

  1990cited by this paper
• Dose-related effects of succinylcholine on the adductor pollicis and masséter muscles in children

  1990cited by this paper
• Is There a Relationship Between Masseteric Muscle Spasm and Malignant Hyperpyrexia?

  1990cited by this paper
• IS THERE A RELATIONSHIP BETWEEN MASSETERIC MUSCLE SPASM AND MALIGNANT HYPERPYREXIA

  1989cited by this paper
• Underdosage with succinylcholine may lead to incorrect diagnosis of masseter spasm in children.

  1988cited by this paper
• Prediction of malignant hyperthermia susceptibility by clinical signs.

  1987cited by this paper
• The Effects of Succinylcholine on Mouth Opening

  1987cited by this paper
• Trismus is not trivial.

  1987cited by this paper
• >Halothane Selectively Attenuates α2‐Adrenoceptor Mediated Vasoconstriction, In Vivo and In Vitro

  1986cited by this paper
• HIGH FREQUENCY CONVENTIONAL VENTILATION ALSO MINIMIZES RESPIRATORY-RELATED MOVEMENT OF KIDNEY STONES DURING ESWL IS IT, HOWEVER, INDICATED?

  1986cited by this paper
• Masseter Muscle Rigidity and Malignant Hyperthermia Susceptibility

  1986cited by this paper
• Treatment of heat stroke with dantrolene.

  1981cited by this paper
• Implications of masseter spasm after succinylcholine.

  1978cited by this paper
• Malignant hypertonic hyperpyrexia syndrome.

  1970cited by this paper
• Malignant hypertonic hyperpyrexia syndrome

  1969cited by this paper

• Peri-Operative Nursing of Patients with Malignant Hyperthermia: A Narrative Literature Review

  2025cites this paper
• The Effectiveness of a Mobile National Remote Emergency System for Malignant Hyperthermia in China: Retrospective Pre-Post Implementation Study

  2025cites this paper
• Perioperative Resuscitation and Life Support (PeRLS): An Update.

  2025cites this paper
• Iatrogenic malignant hyperthermia during cesarean section

  2025cites this paper
• Злокачественная гипертермия как анестезиологическая проблема: обзор литературы

  2025cites this paper
• Case Report of the Use of an Intravascular Cooling Device in the Management of Malignant Hyperthermia

  2024cites this paper
• Majoring on the minors: Regulatory organizations turn a blind eye to emergency department boarding in favor of rare conditions

  2024cites this paper
• Case Report of Malignant Hyperthermia in the Emergency Department

  2023cites this paper
• Hyperthermie maligne de l’anesthésie

  2023cites this paper
• Epidemiological and clinical features of malignant hyperthermia: A scoping review

  2023cites this paper
• Evaluation of Malignant Hyperthermia Features in Patients with Pathogenic or Likely Pathogenic RYR1 Variants Disclosed through a Population Genomic Screening Program

  2023cites this paper
• A Single-Center Retrospective Review of Patients with Suspected Malignant Hyperthermia Susceptibility

  2023cites this paper
• The Knowledge Profile, Competence and Pending Problems of Chinese Anesthesiologists in Dealing with Malignant Hyperthermia: A Cross-Sectional Survey

  2023cites this paper
• Management of patients susceptible to malignant hyperthermia: A surgeon's perspective.

  2022cites this paper
• Clinical Features of Suspected Malignant Hyperthermia in China from 2015 to 2020: A Retrospective Study from China Malignant Hyperthermia Emergency Assistance Group

  2022cites this paper
• Crisis Management in Malignant Hyperthermia

  2021cites this paper
• Neurotoxicology Emergencies

  2021cites this paper
• Anesthesia-Related Complications in Neuromuscular Disorders in Adults

  2020cites this paper
• Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group.

  2020cites this paper
• Anaesthesia and neuromuscular disorders: what a neurologist needs to know

  2020cites this paper
• Neuromuscular Urgencies and Emergencies

  2020cites this paper
• Isoflurane Induced Malignant Hyperthermia in a Patient with Glucose 6-Phosphate Dehydrogenase Deficiency and Growth Hormone Abuse

  2020cites this paper
• Fever as an Adverse Drug Reaction of Different Therapeutic Groups

  2020cites this paper
• Skeletal muscle CaV1.1 channelopathies

  2020cites this paper
• Nursing Interventions of Intraoperative Malignant Hyperthermia in Patients With Scoliosis: A Report of 3 Cases.

  2020cites this paper
• Malignant Hyperthermia Update.

  2020cites this paper
• Availability of dantrolene for the management of malignant hyperthermia crises: European Malignant Hyperthermia Group guidelines.

  2020cites this paper
• Cost-benefit relationship of keeping dantrolene stocks from the point of view of healthcare institutions

  2020cites this paper
• Malignant Hyperthermia-Susceptible Adult Patient and Ambulatory Surgery Center: Society for Ambulatory Anesthesia and Ambulatory Surgical Care Committee of the American Society of Anesthesiologists Position Statement.

  2019cites this paper
• Dantrolene Should Be Readily Available Wherever Malignant Hyperthermia Triggering Drugs Are Stocked.

  2019cites this paper
• Boletín informativo

  2019cites this paper